clinical trial · NCT05870839
Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States
Vaccine Company, Inc.·phase1·completed·n = 121
SARS-CoVSARS-CoV-2VXCO-100
brief summary
The purpose of this study is to evaluate the safety and immunogenicity of ascending dose levels of VXCO-100 in healthy adults.
started
May 11, 2023
primary completion
Apr 10, 2024
completion
Apr 10, 2024
last updated
Dec 10, 2024
detailed description
This is a phase 1, multisite clinical trial to evaluate the safety and immunogenicity of 3 dose levels of VXCO-100 in healthy adult volunteers.
Participants will be vaccinated with 1 dose of VXCO-100 on Day 1. A subset of participants will be offered an optional interim boost at month 3.
Safety will be evaluated 1) before proceeding to a higher dose level and 2) prior to enrollment of participants aged 56 years and older at a particular dose level.
official title
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of VXCO-100 in Healthy Adults in the United States
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol